Group One Trading
VIRX

Group One Trading’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Group One Trading’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-600
Closed -$846 – 8452
2023
Q2 		$846 Hold
600
– – ﹤0.01% 7291
2023
Q1 		$954 Sell
600
-4,800
-89% -$8.72K ﹤0.01% 6796
2022
Q4 		$7.88K Hold
5,400
– – ﹤0.01% 6131
2022
Q3 		$23K Hold
5,400
– – ﹤0.01% 5988
2022
Q2 		$21K Hold
5,400
– – ﹤0.01% 6263
2022
Q1 		$26K Sell
5,400
-3,800
-41% -$11.4K ﹤0.01% 6592
2021
Q4 		$34K Sell
9,200
-5,300
-37% -$28.3K ﹤0.01% 6627
2021
Q3 		$116K Sell
14,500
-9,200
-39% -$90.7K ﹤0.01% 5764
2021
Q2 		$269K Buy
23,700
+8,700
+58% +$87.3K ﹤0.01% 4904
2021
Q1 		$139K Buy
15,000
+13,800
+1,150% +$144K ﹤0.01% 5352
2020
Q4 		$8K Sell
1,200
-24,943
-95% -$130K ﹤0.01% 5886
2020
Q3 		$114K Buy
26,143
+25,994
+17,446% +$227K ﹤0.01% 4105
2020
Q2 		$1K Sell
149
-1,071
-88% -$16.1K ﹤0.01% 5687
2020
Q1 		$18K Buy
1,220
+543
+80% +$11.8K ﹤0.01% 4290
2019
Q4 		$8K Sell
677
-300
-31% -$5.02K ﹤0.01% 4665
2019
Q3 		$25K Sell
977
-189
-16% -$5.45K ﹤0.01% 4291
2019
Q2 		$30K Buy
1,166
+817
+234% +$31.6K ﹤0.01% 4023
2019
Q1 		$15K Buy
349
+255
+271% +$5.78K ﹤0.01% 4140
2018
Q4 		$1K Sell
94
-172
-65% -$7.02K ﹤0.01% 4758
2018
Q3 		$19K Buy
266
+20
+8% +$1.52K ﹤0.01% 4408
2018
Q2 		$18K Buy
246
+92
+60% +$8.19K ﹤0.01% 4421
2018
Q1 		$15K Buy
154
+100
+185% +$17.1K ﹤0.01% 4192
2017
Q4 		$7K Sell
54
-6
-10% -$562 ﹤0.01% 4488
2017
Q3 		$4K Buy
60
+51
+567% +$4.16K ﹤0.01% 4548
2017
Q2 		$1K Sell
9
-348
-97% -$39.9K ﹤0.01% 4655
2017
Q1 		$51K Sell
357
-3,763
-91% -$538K ﹤0.01% 3392
2016
Q4 		$522K Buy
4,120
+271
+7% +$37.7K 0.01% 1743
2016
Q3 		$589K Buy
3,849
+3,222
+514% +$455K 0.01% 1698
2016
Q2 		$72K Sell
627
-101
-14% -$11.2K ﹤0.01% 3073
2016
Q1 		$83K Sell
728
-299
-29% -$45.3K ﹤0.01% 2955
2015
Q4 		$194K Sell
1,027
-140
-12% -$26.2K ﹤0.01% 2515
2015
Q3 		$199K Buy
1,167
+439
+60% +$158K ﹤0.01% 2504
2015
Q2 		$460K Sell
728
-529
-42% -$281K 0.01% 1854
2015
Q1 		$647K Sell
1,257
-51
-4% -$25.7K 0.01% 1410
2014
Q4 		$700K Sell
1,308
-2,094
-62% -$944K 0.01% 1309
2014
Q3 		$5.1M Buy
3,402
+3,092
+997% +$4.48M 0.08% 289
2014
Q2 		$425K Sell
310
-416
-57% -$483K 0.01% 1773
2014
Q1 		$1.01M Buy
726
+581
+401% +$676K 0.02% 1083
2013
Q4 		$144K Sell
145
-46
-24% -$47.6K ﹤0.01% 2716
2013
Q3 		$199K Hold
191
– – ﹤0.01% 2392
2013
Q2 		$209K Buy
+191
New +$213K 0.01% 2135

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading's VIRX Position: Q3 2023 in Review

Group One Trading sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2023, closing a stake of 100 shares — an estimated $141 sold.

Group One Trading first reported a position in VIRX in Q2 2013 and held it in 35 quarters. The position peaked at $564K in Q2 2015. 42 funds tracked by Wall St. Rank hold VIRX as of Q3 2023.

  • Group One Trading reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Group One Trading sold 100 Viracta Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $141.
  • Group One Trading first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 35 quarters.
  • Group One Trading's Viracta Therapeutics, Inc. Common Stock position peaked at $564K in Q2 2015.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Group One Trading's 13F filing for Q3 2023, filed 9 Nov 2023.